45O Stock Overview
A biotech company, focuses on cell and gene therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Orgenesis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$7.55 |
| 52 Week Low | US$3.40 |
| Beta | 1.32 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -87.77% |
| 5 Year Change | n/a |
| Change since IPO | -92.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 45O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how 45O performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 45O performed against the German Market.
Price Volatility
| 45O volatility | |
|---|---|
| 45O Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 45O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 45O's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 146 | Vered Caplan | orgenesis.com |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Orgenesis Inc. Fundamentals Summary
| 45O fundamental statistics | |
|---|---|
| Market cap | €5.67m |
| Earnings (TTM) | -€32.85m |
| Revenue (TTM) | €858.10k |
6.6x
P/S Ratio-0.2x
P/E RatioIs 45O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 45O income statement (TTM) | |
|---|---|
| Revenue | US$899.00k |
| Cost of Revenue | US$1.78m |
| Gross Profit | -US$878.00k |
| Other Expenses | US$33.53m |
| Earnings | -US$34.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.66 |
| Gross Margin | -97.66% |
| Net Profit Margin | -3,827.81% |
| Debt/Equity Ratio | -63.2% |
How did 45O perform over the long term?
See historical performance and comparison